Stryker Comprehensive Income 2010-2024 | SYK
Stryker comprehensive income from 2010 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
- Stryker comprehensive income for the quarter ending September 30, 2024 was $-0.545B, a 118.88% increase year-over-year.
- Stryker comprehensive income for 2023 was $-0.416B, a 88.24% increase from 2022.
- Stryker comprehensive income for 2022 was $-0.221B, a 58.38% decline from 2021.
- Stryker comprehensive income for 2021 was $-0.531B, a 54.11% decline from 2020.
| Stryker Annual Comprehensive Income (Millions of US $) |
|
|---|---|
| 2023 | $-416 |
| 2022 | $-221 |
| 2021 | $-531 |
| 2020 | $-1,157 |
| 2019 | $-606 |
| 2018 | $-631 |
| 2017 | $-553 |
| 2016 | $-761 |
| 2015 | $-639 |
| 2014 | $-254 |
| 2013 | $232 |
| 2012 | $129 |
| 2011 | $144 |
| 2010 | $154 |
| 2009 | $258 |
| Stryker Quarterly Comprehensive Income (Millions of US $) |
|
|---|---|
| 2024-09-30 | $-545 |
| 2024-06-30 | $-355 |
| 2024-03-31 | $-377 |
| 2023-12-31 | $-416 |
| 2023-09-30 | $-249 |
| 2023-06-30 | $-330 |
| 2023-03-31 | $-305 |
| 2022-12-31 | $-221 |
| 2022-09-30 | $-89 |
| 2022-06-30 | $-286 |
| 2022-03-31 | $-479 |
| 2021-12-31 | $-531 |
| 2021-09-30 | $-816 |
| 2021-06-30 | $-943 |
| 2021-03-31 | $-867 |
| 2020-12-31 | $-1,157 |
| 2020-09-30 | $-917 |
| 2020-06-30 | $-715 |
| 2020-03-31 | $-623 |
| 2019-12-31 | $-606 |
| 2019-09-30 | $-553 |
| 2019-06-30 | $-630 |
| 2019-03-31 | $-565 |
| 2018-12-31 | $-631 |
| 2018-09-30 | $-604 |
| 2018-06-30 | $-557 |
| 2018-03-31 | $-510 |
| 2017-12-31 | $-553 |
| 2017-09-30 | $-498 |
| 2017-06-30 | $-590 |
| 2017-03-31 | $-675 |
| 2016-12-31 | $-761 |
| 2016-09-30 | $-600 |
| 2016-06-30 | $-595 |
| 2016-03-31 | $-622 |
| 2015-12-31 | $-639 |
| 2015-09-30 | $-529 |
| 2015-06-30 | $-431 |
| 2015-03-31 | $-521 |
| 2014-12-31 | $-254 |
| 2014-09-30 | $-74 |
| 2014-06-30 | $231 |
| 2014-03-31 | $268 |
| 2013-12-31 | $232 |
| 2013-09-30 | $146 |
| 2013-06-30 | $31 |
| 2013-03-31 | $17 |
| 2012-12-31 | $129 |
| 2012-09-30 | $78 |
| 2012-06-30 | $-60 |
| 2012-03-31 | $235 |
| 2011-12-31 | $144 |
| 2011-09-30 | $272 |
| 2011-06-30 | $484 |
| 2011-03-31 | $416 |
| 2010-12-31 | $154 |
| 2010-09-30 | $210 |
| 2010-06-30 | $-52 |
| 2010-03-31 | $152 |
| 2009-12-31 | $258 |
| 2009-09-30 | $327 |
| 2009-06-30 | $189 |
| 2009-03-31 | $69 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $143.322B | $20.498B |
| Stryker Corporation is a medical device company operating in the global orthopedic market. The company has three business segments: Orthopaedics, MedSurg and Neurotechnology & Spine. Orthopaedic?products include implants used in hip and knee joint replacements and trauma and extremities surgeries. MedSurg?products consists of surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment and reprocessed and remanufactured medical devices. Neurotechnology & Spine division includes both neurosurgical and neurovascular devices. These includes products used for minimally invasive endovascular techniques; traditional brain and open skull base surgical procedures; orthobiologic and biosurgery products and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. Spinal implant product offering includes cervical, thoracolumbar and interbody systems used in spinal injury, deformity and degenerative therapies. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $202.220B | 25.79 |
| Boston Scientific (BSX) | United States | $130.065B | 37.39 |
| Medtronic (MDT) | Ireland | $112.498B | 16.74 |
| EssilorLuxottica (ESLOY) | France | $111.686B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $45.423B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.501B | 28.26 |
| GE HealthCare Technologies (GEHC) | United States | $39.264B | 20.36 |
| ResMed (RMD) | United States | $37.048B | 30.44 |
| Terumo (TRUMY) | Japan | $29.575B | 41.77 |
| Koninklijke Philips (PHG) | Netherlands | $25.012B | 19.14 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.536B | 13.71 |
| Insulet (PODD) | United States | $18.791B | 74.86 |
| Baxter (BAX) | United States | $17.673B | 11.51 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.619B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $10.338B | 35.13 |
| BellRing Brands (BRBR) | United States | $9.136B | 38.63 |
| Demant (WILYY) | Denmark | $8.351B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.084B | 14.14 |
| Haemonetics (HAE) | United States | $4.474B | 21.43 |
| TG Therapeutics (TGTX) | United States | $4.460B | 0.00 |
| ICU Medical (ICUI) | United States | $4.318B | 41.21 |
| Prestige Consumer Healthcare (PBH) | United States | $3.983B | 19.75 |
| Perrigo (PRGO) | Ireland | $3.596B | 10.59 |
| Neogen (NEOG) | United States | $3.517B | 40.57 |
| Envista Holdings (NVST) | United States | $3.509B | 26.14 |
| Agios Pharmaceuticals (AGIO) | United States | $3.368B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $3.041B | 19.50 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| QuidelOrtho (QDEL) | United States | $2.942B | 18.94 |
| LeMaitre Vascular (LMAT) | United States | $2.342B | 56.97 |
| Warby Parker (WRBY) | United States | $1.964B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.888B | 33.04 |
| AtriCure (ATRC) | United States | $1.826B | 0.00 |
| InMode (INMD) | Israel | $1.630B | 9.80 |
| Curaleaf Holdings (CURLF) | Canada | $1.384B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.357B | 9.70 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.280B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.206B | 0.00 |
| Owens & Minor (OMI) | United States | $0.995B | 7.77 |
| Phibro Animal Health (PAHC) | United States | $0.966B | 17.04 |
| CeriBell (CBLL) | United States | $0.962B | 0.00 |
| National Vision Holdings (EYE) | United States | $0.906B | 30.29 |
| Capricor Therapeutics (CAPR) | United States | $0.895B | 0.00 |
| Evolus (EOLS) | United States | $0.866B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.691B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.605B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.582B | 17.56 |
| Quanterix (QTRX) | United States | $0.580B | 0.00 |
| Surmodics (SRDX) | United States | $0.549B | 0.00 |
| Valneva SE (VALN) | France | $0.426B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.398B | 0.00 |
| ZimVie (ZIMV) | United States | $0.393B | 33.12 |
| Viemed Healthcare (VMD) | United States | $0.353B | 33.59 |
| Cerus (CERS) | United States | $0.331B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.320B | 21.45 |
| Sanara MedTech (SMTI) | United States | $0.308B | 0.00 |
| Biote (BTMD) | United States | $0.301B | 13.90 |
| Zynex (ZYXI) | United States | $0.287B | 60.07 |
| Jin Medical (ZJYL) | China | $0.284B | 0.00 |
| MacroGenics (MGNX) | United States | $0.273B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.269B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.264B | 0.00 |
| Omeros (OMER) | United States | $0.256B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.236B | 15.90 |
| High Tide (HITI) | Canada | $0.221B | 91.67 |
| Brainsway (BWAY) | Israel | $0.181B | 217.20 |
| Organigram Holdings (OGI) | Canada | $0.172B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.151B | 20.39 |
| Rockwell Medical (RMTI) | United States | $0.137B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.129B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.116B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.111B | 0.00 |
| Veru (VERU) | United States | $0.107B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.104B | 0.00 |
| Fonar (FONR) | United States | $0.095B | 9.82 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.094B | 23.10 |
| Cellectar Biosciences (CLRB) | United States | $0.086B | 0.00 |
| Sanuwave Health (SNWVD) | United States | $0.079B | 2.67 |
| Modular Medical (MODD) | United States | $0.072B | 0.00 |
| InterCure (INCR) | Israel | $0.070B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.070B | 0.00 |
| MariMed (MRMD) | United States | $0.062B | 0.00 |
| Safety Shot (SHOT) | United States | $0.062B | 0.00 |
| Apyx Medical (APYX) | United States | $0.053B | 0.00 |
| Exagen (XGN) | United States | $0.050B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.048B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.040B | 0.00 |
| ImmuCell (ICCC) | United States | $0.028B | 0.00 |
| Flora Growth (FLGC) | United States | $0.017B | 0.00 |
| Nephros (NEPH) | United States | $0.017B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.012B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.012B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.008B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Agape ATP (ATPC) | $0.006B | 0.00 | |
| Sharps Technology (STSS) | United States | $0.005B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| Leafly Holdings (LFLY) | United States | $0.004B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| Senestech (SNES) | United States | $0.001B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 14.20 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |